Skip to main content

Zacks Investment Research enhanced actions of Griffols (NASDAQ: GRFSGet a rating) from a sell rating to a hold rating in a research note published on Friday, Zacks.com reports.

According to Zacks, “Grifols, SA, operates in the pharmaceutical-hospital sector engaged in the research, development and retail sale of plasma derivatives, products for intravenous therapy, clinical nutrition, diagnostic systems and logistics hospital. The Company operates through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and marketing of plasma derivatives. The Diagnostics division focuses on the research, development, manufacture and marketing of diagnostic products for laboratory analysis, including products for hospital blood banks and transfusion centers. The Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, SA is based in Barcelona, ​​Spain. “

A number of other brokerages have also recently released reports on GRFS. Berenberg Bank lowered its price target on Grifols from €21.60 ($23.48) to €21.40 ($23.26) in a Thursday, March 3 report. JPMorgan Chase & Co. lowered its price target on Grifols from €15.00 ($16.30) to €11.00 ($11.96) in a Tuesday, January 4 report. StockNews.com began covering Grifols in a report on Thursday, March 31. They issued a holding note for the company. Finally, Morgan Stanley began covering Grifols in a report on Friday, April 8. They issued a rating of equal weight for the company. One research analyst has assigned the stock a sell rating, four have assigned a hold rating and three have assigned the stock a buy rating. Based on MarketBeat data, Grifols has a consensus rating of Hold and a consensus price target of $16.20.

Shares of GRFS opened at $10.76 on Friday. The stock has a 50-day moving average price of $11.25 and a 200-day moving average price of $11.93. The company has a quick ratio of 0.94, a current ratio of 1.59 and a leverage ratio of 0.85. The company has a market capitalization of $7.30 billion, a price-earnings ratio of 9.44 and a beta of 0.40. Grifols has a 52-week low of $10.10 and a 52-week high of $19.07.

Several hedge funds have recently bought and sold shares of GRFS. Norges Bank acquired a new stake in Grifols shares in the fourth quarter valued at approximately $38,959,000. Capital World Investors increased its stake in Grifols shares by 14.9% during the fourth quarter. Capital World Investors now owns 14,907,138 shares of the biotech company worth $167,407,000 after buying an additional 1,932,123 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Grifols shares by 448.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,240,331 shares of the biotech company worth $32,731,000 after purchasing an additional 1,831,499 shares in the last quarter. Flat Footed LLC purchased a new stake in Grifols stock during the fourth quarter worth approximately $12,983,000. Finally, Citigroup Inc. increased its stake in Grifols shares by 200.8% during the third quarter. Citigroup Inc. now owns 915,485 shares of the biotech company worth $13,375,000 after buying an additional 611,114 shares in the last quarter. 13.83% of the shares are held by institutional investors and hedge funds.

About Grifols (Get a rating)

Grifols, SA deals with the supply, manufacture, preparation and sale of therapeutic products, mainly hemoderivatives. The Company operates through Bioscience, Hospital, Diagnostics, Bio Supplies and Others divisions. The Bioscience division researches, develops, produces and markets plasma-derived drugs and other innovative solutions to treat patients with chronic, rare, prevalent and life-threatening diseases.

See also

Get a Free Copy of Zacks Research Report on Grifols (GRFS)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Analyst Recommendations for Grifols (NASDAQ:GRFS)



Get news and reviews for Grifols Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Grifols and related companies with MarketBeat.com’s FREE daily email newsletter.